share_log

CRISPR Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Bruno Julianne

CRISPR Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Bruno Julianne

CRISPR Therapeutics | 3：首次持股声明-高管 Bruno Julianne
美股sec公告 ·  05/23 16:32
Moomoo AI 已提取核心信息
Julianne Bruno, Chief Operating Officer of CRISPR Therapeutics, filed an Initial Statement of Beneficial Ownership of Securities with the SEC on May 23, 2024. The filing, required under Section 16(a) of the Securities Exchange Act of 1934, details Bruno's direct and indirect ownership of CRISPR Therapeutics' common shares and derivative securities, including stock options and restricted stock units (RSUs). Bruno directly owns 3,111 common shares and indirectly owns 7,088 shares through the Julianne Bruno 2022 GRAT. The filing also lists multiple stock options with varying exercise prices and expiration dates, ranging from May 1, 2029, to March 20, 2034, and RSUs with vesting schedules extending to March 20, 2028. The document outlines the vesting conditions of these securities, indicating a structured plan for share ownership over the coming years.
Julianne Bruno, Chief Operating Officer of CRISPR Therapeutics, filed an Initial Statement of Beneficial Ownership of Securities with the SEC on May 23, 2024. The filing, required under Section 16(a) of the Securities Exchange Act of 1934, details Bruno's direct and indirect ownership of CRISPR Therapeutics' common shares and derivative securities, including stock options and restricted stock units (RSUs). Bruno directly owns 3,111 common shares and indirectly owns 7,088 shares through the Julianne Bruno 2022 GRAT. The filing also lists multiple stock options with varying exercise prices and expiration dates, ranging from May 1, 2029, to March 20, 2034, and RSUs with vesting schedules extending to March 20, 2028. The document outlines the vesting conditions of these securities, indicating a structured plan for share ownership over the coming years.
CRISPR Therapeutics首席运营官朱丽安·布鲁诺于2024年5月23日向美国证券交易委员会提交了初步的证券实益所有权声明。根据1934年《证券交易法》第16（a）条的要求，该文件详细说明了布鲁诺对CRISPR Therapeutics普通股和衍生证券（包括股票期权和限制性股票单位（RSU）的直接和间接所有权。布鲁诺直接拥有3,111股普通股，并通过朱丽安·布鲁诺2022年GRAT间接拥有7,088股股票。该文件还列出了行使价和到期日各不相同的多个股票期权，范围从2029年5月1日到2034年3月20日不等，以及归属时间表延至2028年3月20日的限制性股票单位。该文件概述了这些证券的归属条件，指出了未来几年的结构化股份所有权计划。
CRISPR Therapeutics首席运营官朱丽安·布鲁诺于2024年5月23日向美国证券交易委员会提交了初步的证券实益所有权声明。根据1934年《证券交易法》第16（a）条的要求，该文件详细说明了布鲁诺对CRISPR Therapeutics普通股和衍生证券（包括股票期权和限制性股票单位（RSU）的直接和间接所有权。布鲁诺直接拥有3,111股普通股，并通过朱丽安·布鲁诺2022年GRAT间接拥有7,088股股票。该文件还列出了行使价和到期日各不相同的多个股票期权，范围从2029年5月1日到2034年3月20日不等，以及归属时间表延至2028年3月20日的限制性股票单位。该文件概述了这些证券的归属条件，指出了未来几年的结构化股份所有权计划。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息